Latest News

EUSA Pharma Announces FDA Approval of Phase 3 Clinical Trial for Siltuximab in Hospitalized Patients with COVID-19 Associated Acute Respiratory Distress Syndrome

02/07/2020

Read More …

EUSA Pharma and Papa Giovanni XXIII Hospital, Italy, Provide Interim Analysis Data for Siltuximab-treated COVID-19 Patients from the SISCO Study

01/04/2020

Read More …

EUSA Pharma and the Papa Giovanni XXIII Hospital, Bergamo, Italy announce initiation of an observational case-control study of siltuximab in…

18/03/2020

Read More …

SYLVANT® (siltuximab) Recommended by the National Comprehensive Cancer Network® (NCCN®) Guidelines as a Preferred Treatment Option for Patients with Idiopathic…

10/02/2020

Read More …

EUSA Pharma and BeiGene Announce Exclusive Development and Commercialization Agreement for SYLVANT® and QARZIBA®▼ in Greater China…

13/01/2020

Read More …

EUSA Pharma Announces New QARZIBA® (Dinutuximab Beta) Data to be Presented at 2019 ASCO Annual Meeting…

29/05/2019

Read More …

EUSA Pharma Announces Appointment of Carsten Thiel as President Europe and Darrel P. Cohen as Head of Clinical Development

15/05/2019

Read More …

EUSA Pharma Completes Acquisition of Global Rights to SYLVANT® (siltuximab) and Presents Company Update at 37TH J.P. Morgan Healthcare Conference…

09/01/2019

Read More …

EUSA to Open New US Headquarters in Boston, MA – Significant US Expansion to Complete EUSA’s Transatlantic Commercial Platform

07/12/2018

Read More …

EUSA Pharma Announces Acquisition of Global Rights to SYLVANT® (siltuximab) from Janssen Sciences Ireland UC For $115 Million…

18/07/2018

Read More …

NICE Approves the Targeted Cancer Immunotherapy, QARZIBA®▼ (Dinutuximab Beta) to Treat Children with High-Risk Neuroblastoma…

12/07/2018

Read More …